skip to main content
Idioma:

131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumors - a single center study.

Kotecka-Blicharz, Agnieszka ; Hasse-Lazar, Kornelia ; Handkiewicz-Junak, Daria ; Gawlik, Tomasz ; Pawlaczek, Agnieszka ; Oczko-Wojciechowska, Małgorzata ; Michalik, Barbara ; Szpak-Ulczok, Sylwia ; Krajewska, Jolanta ; Jurecka-Lubieniecka, Beata ; Jarząb, Barbara

Endokrynologia Polska, 2018, Vol.69 (3), p.246-251 [Periódico revisado por pares]

Poland: Wydawnictwo Via Medica

Texto completo disponível

Citações Citado por
  • Título:
    131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumors - a single center study.
  • Autor: Kotecka-Blicharz, Agnieszka ; Hasse-Lazar, Kornelia ; Handkiewicz-Junak, Daria ; Gawlik, Tomasz ; Pawlaczek, Agnieszka ; Oczko-Wojciechowska, Małgorzata ; Michalik, Barbara ; Szpak-Ulczok, Sylwia ; Krajewska, Jolanta ; Jurecka-Lubieniecka, Beata ; Jarząb, Barbara
  • Assuntos: Neuroendocrine tumors ; Tumors
  • É parte de: Endokrynologia Polska, 2018, Vol.69 (3), p.246-251
  • Descrição: Pheochromocytomas and paragangliomas are rare tumors deriving from chromaffin cells of adrenal medulla or paraganglia. They are usually benign but 10-35% of them present malignant behavior. The aim of the study was to evaluate the efficacy and safety of 131-I MIBG therapy in malignant pheochromocytoma /paraganglioma patients (MPPGL). 18 patients (7 women and 11 men) were included in this study. Between 2002 and 2016 they underwent 131-I MIBG therapy because of MPPGL and their medical data were analyzed retrospectively. Clinical indications for the treatment included progressive disease or massive tissue involvement independently from disease progression. Tumor response for the first time was assessed 3 months after the last treatment according to Response Evaluation Criteria in Solid Tumors criteria and by 131-I MIBG scans. The mean single dose used was 7.25 GBq (196 mCi) and mean cumulative dose 33.08 GBq ( 894 mCi). In 2 (11%) patients complete tumor response was achieved. In 1 (6%) patient partial response was obtained. In 13 (72%) patients stable disease was observed. In 2 (11%) patients progression was diagnosed three months after treatment discontinuation. In the whole studied group the progression free survival time was 85 months and overall 5-year survival was 87%. Radionuclide treatment with use of 131-I MIBG may be effective form of palliative treatment for patients with inoperative neoplasm spread, progressive disease or patients requiring alleviation of symptoms.
  • Editor: Poland: Wydawnictwo Via Medica
  • Idioma: Polonês;Inglês
Links
Voltar para lista de resultados
Resultado  1 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.